Clinical trial
Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune…
NCT00162006 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00162006 |
|---|---|
| Title | Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura |
| Official title | Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Immune Thrombocytopenic Purpura (ITP) |
| Intervention type | Drug |
| Interventions | Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution |
| Enrollment | 28 |
| Start date | Jan 13, 2003 |
| Primary completion | Dec 3, 2003 |
| Completion | Dec 3, 2003 |
| First posted | Sep 13, 2005 |
| Last update posted | May 3, 2021 |
| Countries | Czechia, Germany, Hungary, Poland |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: